{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T06:43:47Z","timestamp":1783665827544,"version":"3.55.0"},"reference-count":50,"publisher":"Oxford University Press (OUP)","issue":"12","license":[{"start":{"date-parts":[[2020,1,22]],"date-time":"2020-01-22T00:00:00Z","timestamp":1579651200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R24AI136618"],"award-info":[{"award-number":["R24AI136618"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["2R01-AI060466"],"award-info":[{"award-number":["2R01-AI060466"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01-AI120765"],"award-info":[{"award-number":["R01-AI120765"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,6,11]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>HIV-1 and HIV-2 differ in their antiretroviral (ARV) susceptibilities and drug resistance mutations (DRMs).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We analyzed published HIV-2 pol sequences to identify HIV-2 treatment-selected mutations (TSMs). Mutation prevalences were determined by HIV-2 group and ARV status. Nonpolymorphic mutations were those in &amp;lt;1% of ARV-naive persons. TSMs were those associated with ARV therapy after multiple comparisons adjustment.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>We analyzed protease (PR) sequences from 483 PR inhibitor (PI)-naive and 232 PI-treated persons; RT sequences from 333 nucleoside RT inhibitor (NRTI)-naive and 252 NRTI-treated persons; and integrase (IN) sequences from 236 IN inhibitor (INSTI)-naive and 60 INSTI-treated persons. In PR, 12 nonpolymorphic TSMs occurred in \u226511 persons: V33I, K45R, V47A, I50V, I54M, T56V, V62A, A73G, I82F, I84V, F85L, L90M. In RT, 9 nonpolymorphic TSMs occurred in \u226510 persons: K40R, A62V, K70R, Y115F, Q151M, M184VI, S215Y. In IN, 11 nonpolymorphic TSMs occurred in \u22654 persons: Q91R, E92AQ, T97A, G140S, Y143G, Q148R, A153G, N155H, H156R, R231 5-amino acid insertions. Nine of 32 nonpolymorphic TSMs were previously unreported.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>This meta-analysis confirmed the ARV association of previously reported HIV-2 DRMs and identified novel TSMs. Genotypic and phenotypic studies of HIV-2 TSMs will improve approaches to predicting HIV-2 ARV susceptibility and treating HIV-2\u2013infected persons.<\/jats:p><\/jats:sec>","DOI":"10.1093\/infdis\/jiaa026","type":"journal-article","created":{"date-parts":[[2020,1,18]],"date-time":"2020-01-18T04:25:13Z","timestamp":1579321513000},"page":"1962-1972","source":"Crossref","is-referenced-by-count":19,"title":["Expanded Spectrum of Antiretroviral-Selected Mutations in Human Immunodeficiency Virus Type 2"],"prefix":"10.1093","volume":"221","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2876-1552","authenticated-orcid":false,"given":"Philip L","family":"Tzou","sequence":"first","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine, Stanford University, Stanford, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diane","family":"Descamps","sequence":"first","affiliation":[{"name":"Laboratoire de Virologie, H\u00f4pital Bichat-Claude Bernard, APHP.Nord Universite de Paris, France"},{"name":"INSERM UMR 1137, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soo-Yon","family":"Rhee","sequence":"first","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine, Stanford University, Stanford, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dana N","family":"Raugi","sequence":"first","affiliation":[{"name":"Department of Medicine, University of Washington, Seattle, Washington, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte","family":"Charpentier","sequence":"first","affiliation":[{"name":"Laboratoire de Virologie, H\u00f4pital Bichat-Claude Bernard, APHP.Nord Universite de Paris, France"},{"name":"INSERM UMR 1137, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nuno","family":"Taveira","sequence":"first","affiliation":[{"name":"Research Institute for Medicines, Faculty of Pharmacy, University of Lisbon, Lisbon, Portugal"},{"name":"Instituto Universit\u00e1rio Egas Moniz, Monte da Caparica, Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert A","family":"Smith","sequence":"first","affiliation":[{"name":"Department of Medicine, University of Washington, Seattle, Washington, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vicente","family":"Soriano","sequence":"first","affiliation":[{"name":"Health Sciences School and Medical Center, Universidad Internacional de La Rioja, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"de Mendoza","sequence":"first","affiliation":[{"name":"Puerta de Hierro University Hospital and Research Institute, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan P","family":"Holmes","sequence":"first","affiliation":[{"name":"Department of Statistics, Stanford University, Stanford, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geoffrey S","family":"Gottlieb","sequence":"first","affiliation":[{"name":"Department of Medicine, University of Washington, Seattle, Washington, USA"},{"name":"Department of Global Health, University of Washington, Seattle, Washington, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert W","family":"Shafer","sequence":"first","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine, Stanford University, Stanford, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,1,22]]},"reference":[{"key":"2020061115551640100_CIT0001","doi-asserted-by":"crossref","first-page":"e390","DOI":"10.1016\/S2352-3018(18)30094-8","article-title":"90-90-90 for HIV-2? Ending the HIV-2 epidemic by enhancing care and clinical management of patients infected with HIV-2","volume":"5","author":"Gottlieb","year":"2018","journal-title":"Lancet HIV"},{"key":"2020061115551640100_CIT0002","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1126\/science.7915856","article-title":"Reduced rate of disease development after HIV-2 infection as compared to HIV-1","volume":"265","author":"Marlink","year":"1994","journal-title":"Science"},{"key":"2020061115551640100_CIT0003","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1056\/NEJMc1210334","article-title":"Effect of HIV-2 infection on HIV-1 disease progression","volume":"367","author":"van Tienen","year":"2012","journal-title":"N Engl J Med"},{"key":"2020061115551640100_CIT0004","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1097\/00002030-199311000-00002","article-title":"Cellular and plasma viral load in patients infected with HIV-2","volume":"7","author":"Simon","year":"1993","journal-title":"AIDS"},{"key":"2020061115551640100_CIT0005","article-title":"Long-term follow-up of HIV-2-related AIDS and mortality in Guinea-Bissau: a prospective open cohort study","author":"Esbjornsson","journal-title":"Lancet HIV"},{"key":"2020061115551640100_CIT0006","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.antiviral.2013.12.001","article-title":"Antiretroviral therapy and drug resistance in human immunodeficiency virus type 2 infection","volume":"102","author":"Men\u00e9ndez-Arias","year":"2014","journal-title":"Antiviral Res"},{"key":"2020061115551640100_CIT0007","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1159\/000332025","article-title":"Special aspects of the treatment of HIV-2-infected patients","volume":"55","author":"Camacho","year":"2012","journal-title":"Intervirology"},{"key":"2020061115551640100_CIT0008","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.1097\/QAD.0b013e32833f9e36","article-title":"In-vitro phenotypic susceptibility of HIV-2 clinical isolates to the integrase inhibitor S\/GSK1349572","volume":"24","author":"Charpentier","year":"2010","journal-title":"AIDS"},{"key":"2020061115551640100_CIT0009","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1086\/596504","article-title":"Emergence of multiclass drug-resistance in HIV-2 in antiretroviral-treated individuals in Senegal: implications for HIV-2 treatment in resource-limited West Africa","volume":"48","author":"Gottlieb","year":"2009","journal-title":"Clin Infect Dis"},{"key":"2020061115551640100_CIT0010","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1097\/01.aids.0000196171.35056.6c","article-title":"High rate of proV47A selection in HIV-2 patients failing lopinavir-based HAART","volume":"20","author":"Rod\u00e9s","year":"2006","journal-title":"AIDS"},{"key":"2020061115551640100_CIT0011","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1002\/jmv.20296","article-title":"Polymorphism and drug-selected mutations in the reverse transcriptase gene of HIV-2 from patients living in southeastern France","volume":"75","author":"Colson","year":"2005","journal-title":"J Med Virol"},{"key":"2020061115551640100_CIT0012","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1002\/jmv.20174","article-title":"High frequency of selection of K65R and Q151M mutations in HIV-2 infected patients receiving nucleoside reverse transcriptase inhibitors containing regimen","volume":"74","author":"Descamps","year":"2004","journal-title":"J Med Virol"},{"key":"2020061115551640100_CIT0013","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1128\/JCM.43.1.484-487.2005","article-title":"Polymorphism of the human immunodeficiency virus type 2 (HIV-2) protease gene and selection of drug resistance mutations in HIV-2-infected patients treated with protease inhibitors","volume":"43","author":"Damond","year":"2005","journal-title":"J Clin Microbiol"},{"key":"2020061115551640100_CIT0014","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1097\/01.aids.0000233582.64467.8e","article-title":"Virological and immunological response to Combivir and emergence of drug resistance mutations in a cohort of HIV-2 patients in The Gambia","volume":"20","author":"Jallow","year":"2006","journal-title":"AIDS"},{"key":"2020061115551640100_CIT0015","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1093\/jac\/dkl034","article-title":"Susceptibility to protease inhibitors in HIV-2 primary isolates from patients failing antiretroviral therapy","volume":"57","author":"Rod\u00e9s","year":"2006","journal-title":"J Antimicrob Chemother"},{"key":"2020061115551640100_CIT0016","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1128\/JCM.42.2.570-577.2004","article-title":"Polymorphism and drug-selected mutations in the protease gene of human immunodeficiency virus type 2 from patients living in Southern France","volume":"42","author":"Colson","year":"2004","journal-title":"J Clin Microbiol"},{"key":"2020061115551640100_CIT0017","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1093\/jac\/dks363","article-title":"Mutations selected in HIV-2-infected patients failing a regimen including atazanavir","volume":"68","author":"Cavaco-Silva","year":"2013","journal-title":"J Antimicrob Chemother"},{"key":"2020061115551640100_CIT0018","doi-asserted-by":"crossref","first-page":"2751","DOI":"10.1128\/AAC.00405-13","article-title":"Complex patterns of protease inhibitor resistance among antiretroviral treatment-experienced HIV-2 patients from Senegal: implications for second-line therapy","volume":"57","author":"Raugi","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"2020061115551640100_CIT0019","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1097\/QAD.0000000000000244","article-title":"Genotypic resistance profiles of HIV-2-treated patients in West Africa","volume":"28","author":"Charpentier","year":"2014","journal-title":"AIDS"},{"key":"2020061115551640100_CIT0020","first-page":"1521","article-title":"Dolutegravir in HIV-2-infected patients with resistant virus to first-line integrase inhibitors from the French named patient program","volume":"60","author":"Descamps","year":"2015","journal-title":"Clin Infect Dis"},{"key":"2020061115551640100_CIT0021","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1128\/JVI.02259-14","article-title":"Mutation V111I in HIV-2 reverse transcriptase increases the fitness of the nucleoside analogue-resistant K65R and Q151M viruses","volume":"89","author":"Deuzing","year":"2015","journal-title":"J Virol"},{"key":"2020061115551640100_CIT0022","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1093\/jac\/dkx090","article-title":"Drug resistance mutations in HIV-2 patients failing raltegravir and influence on dolutegravir response","volume":"72","author":"Requena","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"2020061115551640100_CIT0023","article-title":"A new mechanism of resistance of HIV-2 to integrase inhibitors: a 5 amino-acids insertion in the integrase C-terminal domain","author":"Le Hingrat","journal-title":"Clin Infect Dis"},{"key":"2020061115551640100_CIT0024","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1093\/jac\/dkz007","article-title":"Clinical experience with integrase inhibitors in HIV-2-infected individuals in Spain","volume":"74","author":"Requena","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"2020061115551640100_CIT0025","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1186\/1742-4690-8-68","article-title":"G140S\/Q148R and N155H mutations render HIV-2 Integrase resistant to raltegravir whereas Y143C does not","volume":"8","author":"Ni","year":"2011","journal-title":"Retrovirology"},{"key":"2020061115551640100_CIT0026","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1097\/QAI.0b013e31827b55f1","article-title":"HIV-2 antiviral potency and selection of drug resistance mutations by the integrase strand transfer inhibitor elvitegravir and NRTIs emtricitabine and tenofovir in vitro","volume":"62","author":"Andreatta","year":"2013","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2020061115551640100_CIT0027","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1086\/597802","article-title":"Antiretroviral drug resistance in HIV-2: three amino acid changes are sufficient for classwide nucleoside analogue resistance","volume":"199","author":"Smith","year":"2009","journal-title":"J Infect Dis"},{"key":"2020061115551640100_CIT0028","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.1097\/QAD.0b013e32834d8e52","article-title":"Phenotypic susceptibility of HIV-2 to raltegravir: integrase mutations Q148R and N155H confer raltegravir resistance","volume":"25","author":"Smith","year":"2011","journal-title":"AIDS"},{"key":"2020061115551640100_CIT0029","doi-asserted-by":"crossref","first-page":"e45372","DOI":"10.1371\/journal.pone.0045372","article-title":"Three main mutational pathways in HIV-2 lead to high-level raltegravir and elvitegravir resistance: implications for emerging HIV-2 treatment regimens","volume":"7","author":"Smith","year":"2012","journal-title":"PLoS One"},{"key":"2020061115551640100_CIT0030","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s12977-015-0146-8","article-title":"In vitro activity of dolutegravir against wild-type and integrase inhibitor-resistant HIV-2","volume":"12","author":"Smith","year":"2015","journal-title":"Retrovirology"},{"key":"2020061115551640100_CIT0031","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1128\/AAC.01284-07","article-title":"In vitro phenotypic susceptibility of human immunodeficiency virus type 2 clinical isolates to protease inhibitors","volume":"52","author":"Desbois","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"2020061115551640100_CIT0032","author":"Los Alamos National Laboratories","year":"2018"},{"key":"2020061115551640100_CIT0033","doi-asserted-by":"crossref","first-page":"e144","DOI":"10.1093\/nar\/gku739","article-title":"COMET: adaptive context-based modeling for ultrafast HIV-1 subtype identification","volume":"42","author":"Struck","year":"2014","journal-title":"Nucleic Acids Res"},{"key":"2020061115551640100_CIT0034","doi-asserted-by":"crossref","first-page":"726","DOI":"10.2105\/AJPH.86.5.726","article-title":"Adjusting for multiple testing when reporting research results: the Bonferroni vs Holm methods","volume":"86","author":"Aickin","year":"1996","journal-title":"Am J Public Health"},{"key":"2020061115551640100_CIT0035","author":"Csardi","year":"2018"},{"key":"2020061115551640100_CIT0036","doi-asserted-by":"crossref","first-page":"14410","DOI":"10.1073\/pnas.222366699","article-title":"Structure of HIV-2 reverse transcriptase at 2.35-A resolution and the mechanism of resistance to non-nucleoside inhibitors","volume":"99","author":"Ren","year":"2002","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2020061115551640100_CIT0037","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1074\/jbc.RA117.000177","article-title":"Amino acid residues in HIV-2 reverse transcriptase that restrict the development of nucleoside analogue resistance through the excision pathway","volume":"293","author":"\u00c1lvarez","year":"2018","journal-title":"J Biol Chem"},{"key":"2020061115551640100_CIT0038","doi-asserted-by":"crossref","first-page":"e10","DOI":"10.1371\/journal.ppat.0020010","article-title":"Why do HIV-1 and HIV-2 use different pathways to develop AZT resistance?","volume":"2","author":"Boyer","year":"2006","journal-title":"PLoS Pathog"},{"key":"2020061115551640100_CIT0039","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1128\/JVI.01772-15","article-title":"Four amino acid changes in HIV-2 protease confer class-wide sensitivity to protease inhibitors","volume":"90","author":"Raugi","year":"2016","journal-title":"J Virol"},{"key":"2020061115551640100_CIT0040","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1002\/pro.2019","article-title":"Critical differences in HIV-1 and HIV-2 protease specificity for clinical inhibitors","volume":"21","author":"Tie","year":"2012","journal-title":"Protein Sci"},{"key":"2020061115551640100_CIT0041","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1177\/135965350501000702","article-title":"In vitro phenotypic susceptibility to nucleoside reverse transcriptase inhibitors of HIV-2 isolates with the Q151M mutation in the reverse transcriptase gene","volume":"10","author":"Damond","year":"2005","journal-title":"Antivir Ther"},{"key":"2020061115551640100_CIT0042","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/1471-2334-8-21","article-title":"Transmitted drug resistance, selection of resistance mutations and moderate antiretroviral efficacy in HIV-2: analysis of the HIV-2 Belgium and Luxembourg database","volume":"8","author":"Ruelle","year":"2008","journal-title":"BMC Infect Dis"},{"key":"2020061115551640100_CIT0043","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1093\/jac\/dkr164","article-title":"Drug resistance mutations in patients infected with HIV-2 living in Spain","volume":"66","author":"Trevi\u00f1o","year":"2011","journal-title":"J Antimicrob Chemother"},{"key":"2020061115551640100_CIT0044","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1016\/j.bbrc.2019.05.064","article-title":"Structural studies of antiviral inhibitor with HIV-1 protease bearing drug resistant substitutions of V32I, I47V and V82I","volume":"514","author":"Pawar","year":"2019","journal-title":"Biochem Biophys Res Commun"},{"key":"2020061115551640100_CIT0045","doi-asserted-by":"crossref","first-page":"5885","DOI":"10.1128\/JVI.06597-11","article-title":"HIV-1 and HIV-2 reverse transcriptases: different mechanisms of resistance to nucleoside reverse transcriptase inhibitors","volume":"86","author":"Boyer","year":"2012","journal-title":"J Virol"},{"key":"2020061115551640100_CIT0046","doi-asserted-by":"crossref","first-page":"3075","DOI":"10.1128\/AAC.00146-07","article-title":"In vitro selection and characterization of human immunodeficiency virus type 2 with decreased susceptibility to lopinavir","volume":"51","author":"Masse","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"2020061115551640100_CIT0047","doi-asserted-by":"crossref","first-page":"3611","DOI":"10.1128\/AAC.00154-09","article-title":"Antiretroviral drug resistance in human immunodeficiency virus type 2","volume":"53","author":"Ntemgwa","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"2020061115551640100_CIT0048","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1089\/aid.2018.0282","article-title":"Partial pol sequences from drug naive HIV-2 infected individuals from Maharashtra, India","volume":"35","author":"Ambike","year":"2019","journal-title":"AIDS Res Hum Retroviruses"},{"key":"2020061115551640100_CIT0049","doi-asserted-by":"crossref","first-page":"1790","DOI":"10.1086\/599107","article-title":"Presence of a multidrug-resistance mutation in an HIV-2 variant infecting a treatment-naive individual in Caio, Guinea Bissau","volume":"48","author":"Jallow","year":"2009","journal-title":"Clin Infect Dis"},{"key":"2020061115551640100_CIT0050","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1097\/QAD.0000000000001343","article-title":"Cabotegravir long acting injection protects macaques against intravenous challenge with SIVmac251","volume":"31","author":"Andrews","year":"2017","journal-title":"AIDS"}],"container-title":["The Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jid\/advance-article-pdf\/doi\/10.1093\/infdis\/jiaa026\/32519855\/jiaa026.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jid\/article-pdf\/221\/12\/1962\/33379694\/jiaa026.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jid\/article-pdf\/221\/12\/1962\/33379694\/jiaa026.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,11]],"date-time":"2022-10-11T21:33:03Z","timestamp":1665523983000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jid\/article\/221\/12\/1962\/5713448"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,22]]},"references-count":50,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2020,1,22]]},"published-print":{"date-parts":[[2020,6,11]]}},"URL":"https:\/\/doi.org\/10.1093\/infdis\/jiaa026","relation":{},"ISSN":["0022-1899","1537-6613"],"issn-type":[{"value":"0022-1899","type":"print"},{"value":"1537-6613","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,6,15]]},"published":{"date-parts":[[2020,1,22]]}}}